Measurement of the Folate Receptor in Blood
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The folate receptor (FR) is a cell marker that is over expressed on the cell surface of certain cancers, this occurs most frequently in ovarian cancers. Some normal tissues also express the FR, however in these normal tissues the FR is usually located on the tissue surface that is inaccessible to circulating drugs. As such, drugs which target the FR may potentially be used to achieve anti-tumour efficacy whilst reducing toxicity to normal tissues. Therefore the ability to measure FR levels from different cancer types may help to select patients who are most likely to benefit from treatment with FR targeted therapies. One such drug BGC 945 is currently being tested in preclinical study at The Institute of Cancer Research
| Condition |
|---|
|
Healthy |
| Study Type: | Observational |
| Official Title: | Measurement of the Folate Receptor in Blood |
- To measure the levels of folate receptor in blood samples obtained from patients with ovarian cancer and from healthy volunteers [ Designated as safety issue: No ]
| Estimated Enrollment: | 27 |
| Study Start Date: | September 2008 |
| Estimated Study Completion Date: | July 2011 |
| Estimated Primary Completion Date: | January 2011 (Final data collection date for primary outcome measure) |
A method has been developed in the laboratory which has been able to measure FR obtained from cancer cells in culture that has been added into blood. We would like to study if this method can measure FR in plasma and serum obtained from patients with ovarian cancer. We would also like to analyse plasma and serum samples obtained from healthy volunteers to determine if they have any appreciable levels of FR, which can then be compared to the measurements obtained from cancer patients.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Patients with stage III/IV ovarian cancer
- healthy volunteers who are staff at the ICR and RMH
Exclusion Criteria:
- patients or healthy volunteers who are unable to give informed consent
- pregnancy
Contacts and Locations| Contact: Stan Kaye | 020 8661 3539 | stan.kaye@rmh.nhs.uk |
| Contact: Matthew Ng | 020 8661 3539 | matthew.ng@icr.ac.uk |
| United Kingdom | |
| Royal Marsden NHS Foundation Trust | Recruiting |
| London, Sutton, United Kingdom, SM2 5PT | |
| Contact: Stan Kaye 020 8661 3539 stan.kaye@rmh.nhs.uk | |
| Contact: Matthew Ng 020 8661 3539 matthew.ng@icr.ac.uk | |
| Principal Investigator: Stan Kaye | |
| Royal Marsden NHS Foundation Trust | Recruiting |
| London, Sutton, United Kingdom, SM2 5PT | |
| Contact: Prof Stan Kaye 020 86613538 stan.kaye@rmh.nhs.uk | |
| Contact: Dr Matthew Ng 020 86613538 matthew.ng@icr.ac.uk | |
| Principal Investigator: Prof Stan Kaye | |
| Principal Investigator: | Stan Kaye, Professor | Royal Marsden NHS Foundation Trust |
More Information
No publications provided
| Responsible Party: | Professor Stan Kaye, Royal Marsden NHS Foundation Trust |
| ClinicalTrials.gov Identifier: | NCT00838747 History of Changes |
| Other Study ID Numbers: | CCR3028 |
| Study First Received: | September 5, 2008 |
| Last Updated: | February 5, 2009 |
| Health Authority: | United Kingdom: Research Ethics Committee |
Keywords provided by Royal Marsden NHS Foundation Trust:
|
folate receptor blood samples ovarian cancer development of measure of folate receptor in blood samples possible selection of patients for treatment with FR targeted agents |
Additional relevant MeSH terms:
|
Folic Acid Vitamin B Complex Vitamins Micronutrients Growth Substances |
Physiological Effects of Drugs Pharmacologic Actions Hematinics Hematologic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 23, 2013